IAS 2005: Rio de Janeiro; July 24-27

Key Links:

By Topic:


See Also
A dual-NRTI backbone for multiple patients >

UNBP3028 1/17

The Body PRO Covers: The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

TMC114 Significantly Outperforms Control Protease Inhibitors in Triple-Class-Experienced Patients, Even in Absence of Enfuvirtide

July 27, 2005

The novel protease inhibitor (PI) TMC114 has aroused considerable attention since it began early-stage clinical trials several years ago. At recent conferences, the potency of this molecule in phase 2 clinical trials as an antagonist of HIV replication has been documented.1-3 The current study was designed to assess how ritonavir (RTV, Norvir)-boosted TMC114 compares with other currently approved PIs in patients previously exposed to nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and PIs.

This was a multi-centered, phase 2B efficacy and safety trial led by Christine Katlama, of Hôpital Pitié-Salpêtrière in Paris, France, and colleagues. A total of 318 patients were enrolled. All were currently on stable, PI-based antiretroviral therapy, had a viral load greater than 1,000 copies/mL and had at least 1 primary mutation associated with resistance to PIs. (On average, each patient had previously received 4 different PIs.) At the time of entry, the mean viral load was 4.48 log copies/mL and the average CD4+ cell count was 179 cells/mm3.

Study patients were randomized to 1 of 2 arms. In the first, patients received 1 of 4 different TMC114 + ritonavir doses: 400 mg/100 mg once daily, 400 mg/100 mg twice daily, 600 mg/100 mg twice daily or 800 mg/100 mg once daily. In the second (control) arm, patients received different PIs that had been selected by the clinical investigators. All patients received an optimized background regimen of 2 NRTIs in addition to the selected PI, and were also able to receive enfuvirtide (T-20, Fuzeon).

The 24-week results showed that TMC114 + ritonavir was very well tolerated; only 10% of the 255 patients receiving this drug discontinued therapy, versus 62% of the 63 control patients, with most discontinuations due to virologic failure.

Key 24-week efficacy data is noted in the chart below, in which the most effective TMC114 + ritonavir dose of 600 mg/100 mg twice daily is compared to the control arm, using an intent-to-treat analysis.

 TMC114 600 mg + Ritonavir 100 mgControl Arm
Mean CD4+ cell count increase124 cells/mm320 cells/mm3
% of patients with >1 log viral load reduction77%25%
Mean viral load decline2.03 log10 copies/mL0.63 log10 copies/mL
% of patients achieving viral load <50 copies/mL53%18%

Reductions to less than 50 copies/mL in viral load were seen in 63% of the 19 individuals who received enfuvirtide as well as TMC114 + ritonavir, compared to 56% of individuals who received TMC114 + ritonavir in the absence of enfuvirtide. This was not a statistically significant difference.

These results document the ability of TMC114 + ritonavir to profoundly impact viral load in treatment-experienced individuals whose virus contains primary mutations associated with resistance to currently approved PIs and who had previously failed PI-containing regimens.

Importantly, the benefits of TMC114 + ritonavir did not seem to be particularly dependent on co-administered enfuvirtide in this study. This trial and others like it strongly suggest that TMC114 will be a potent, well-tolerated addition to our armamentarium of PI compounds. Expectations are that it will be effective in individuals who have previously failed PI-containing regimens, and that it will also be an extremely potent drug in patients receiving it as part of first-line therapy.


  1. Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment options: 24-week planned interim analysis of 2 96-week multinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2005; Boston, Mass. Abstract 164LB.

  2. Peeters M, Van Baelen B, De Meyer S, et al. TMC114/RTV activity in multiple PI-experienced patients: correlation of baseline genotype, phenotype, pharmacokinetics, and IQ with antiviral activity at day 14. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, Calif. Abstract 533.

  3. Arasteh K, Clumeck N, Pozniak A, et al. Antiretroviral activity, safety and pharmacokinetics of TMC114, a next-generation HIV-1 protease inhibitor (PI), in multiple PI-experienced patients. In: Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; July 13-16, 2003; Paris, France. Abstract LB16.

Abstract: TMC114/r outperforms investigator-selected PI(s) in 3-class-experienced patients: week 24 primary analysis of POWER 1 (TMC114-C213) (Oral WeOaLB0102)
Authored by: C Katlama, MT Carvalho, D Cooper, K De Backer, E Lefebvre, R Pedro, K Rombouts, A Stoehr, T Vangeneugden, A Woehrmann

Affiliations: Hôpital Pitié-Salpêtrière, Paris, France; Hospital de Clinicas-UFPR, Curitiba, Brazil; University of New South Wales, Sydney, Australia; Tibotec BVBA, Mechelen, Belgium; IFI-Institut im AK St. Ge

It is a part of the publication The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.